Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥18 years of age);~2. American Society of Anesthesiologists (ASA) score I - IV inclusive;~3. Male or female. If female, subject is non-lactating and is either:~   1. Not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.~  2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.~4. Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway. Subjects must meet at least one of the criteria listed below:~   Criteria for Assessing Difficult Airways~   i. History of difficult intubation~   ii. Anticipated difficult airway~  1. Prominent protruding teeth~  2. Small mouth opening~  3. Narrow mandible~  4. Micrognathia~  5. Macroglossia~  6. Short, muscular neck~  7. Very long neck~  8. Limited neck extension~  9. Congenital airway anomalies~  10. Obesity~  11. Known airway pathology~  12. Known airway malignancy~  13. Upper airway obstruction~   iii. Trauma~  1. Face~  2. Upper airway~  3. Cervical spine~   iv. Anticipated difficult mask ventilation~   v. Severe risk of aspiration~   vi. Respiratory failure~   vii. Severe hemodynamic instability~5. Subject (or subject's legally authorized representative) must voluntarily sign and date the informed consent.~Exclusion Criteria:~1. Previous exposure to any experimental drug within 30 days prior to study drug administration;~2. Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak;~3. Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment;~4. Presence of acute alcohol intoxication;~5. Current (within 14 days of study entry) treatment with an α2-agonist or antagonist;~6. Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are contraindicated;~7. Subject received an IV or oral (PO) opioid within one hour or intramuscularly within four hours of the start of study drug administration;~8. Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate \<50 bpm, systolic blood pressure (SBP) \<90 mmHg, or complete heart block unless they have a pacemaker.~9. Subject has elevated serum glutamic pyruvate aminotransferase/alanine transaminase (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase (SGOT/AST) values of ≥2 times the upper limit of normal (ULN).~10. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): Placebo load for 10 min and Placebo maintenance for 15 min

Based on this trial design, predict the completion outcome and termination type (if applicable).